Neumoterol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neumoterol

Property Description
Active ingredients Budesonide, Formoterol fumarate dihydrate
Form Inhalation powder or Inhalation aerosol
Pharmacological class Combination Inhaled Corticosteroid and Long-acting beta2-Agonist (ICS/LABA)
Common use Controller/Maintenance therapy for chronic respiratory conditions
Origin Synthetic

Neumoterol is a fixed-dose combination medication designed for pulmonary delivery via oral inhalation. It belongs to the high-level pharmacological class of an Inhaled Corticosteroid and Long-acting beta2-Agonist (ICS/LABA) combination, a therapeutic strategy recognized as a foundational treatment for stabilizing chronic respiratory issues. This two-part combination approach is clinically recognized for its effectiveness in providing both immediate and sustained improvements in airway function.


What Type of Medicine is Neumoterol?

Neumoterol is defined as a controller therapy, meaning its fundamental purpose is to provide long-term, foundational support for maintaining stable respiratory function, rather than serving as immediate relief for acute symptoms. This synthetic combination product integrates two distinct therapeutic agents into a single device for consistent delivery. This dual ICS/LABA classification distinguishes it from single-ingredient steroid inhalers and rapid-acting bronchodilators, confirming its role in essential maintenance treatment. Other products sharing this active ingredient composition include the widely known brand, Symbicort.

Composition and Pharmaceutical Form

The medicine is composed of two active ingredients: Budesonide and Formoterol. Budesonide is the inhaled corticosteroid component, which provides an anti-inflammatory effect. Formoterol (specifically Formoterol fumarate dihydrate) is the beta2-adrenergic agonist component, acting as a long-acting bronchodilator. Products containing these two agents are utilized for sustained bronchodilation and reducing chronic inflammation. Neumoterol is typically formulated for the route of oral inhalation as either a fine inhalation powder or an inhalation aerosol, utilizing an appropriate excipient or propellant base.

General Therapeutic Purpose

The overall purpose of Neumoterol is to provide comprehensive, sustained control of airway function through two simultaneous actions, a cornerstone of effective controller therapy. The Budesonide component works to reduce chronic swelling and irritation within the air passages. The Formoterol component ensures sustained relaxation of the bronchial smooth muscle, facilitating reliable bronchodilation. This dual mechanism is the essence of its function as a controller, working to maintain open air passages and mitigate the underlying effects of chronic inflammation over time for patients requiring foundational support.

Regulatory References

  1. WHO Essential Medicines List for Budesonide + Formoterol
  2. Budesonide and Formoterol Oral Inhalation Information (MedlinePlus)
  3. Budesonide and Formoterol Drug Label (DailyMed)

What side effects are possible with Neumoterol?

Possible side effects and safety information

The official regulatory safety profile for Neumoterol, a combination of budesonide and formoterol, classifies potential adverse reactions based on their expected frequency and the affected body system. Safety data is grouped into local effects and systemic effects stemming from the inhaled corticosteroid (ICS) and the long-acting beta2-agonist (LABA) components.

Commonly Documented Adverse Reactions

Adverse reactions classified as common in regulatory documents include headache, tremor, and palpitations. Local effects such as oral candidiasis (thrush), dysphonia (hoarseness), and mild throat irritation are also frequently noted. In patients with Chronic Obstructive Pulmonary Disease (COPD), pneumonia is classified as a common occurrence.

Uncommon and Rare Effects

Less frequent, or uncommon, effects include tachycardia, anxiety, depression, and sleep disturbances. Rare and very rare events may involve severe systemic consequences, such as immediate paradoxical bronchospasm or signs of adrenal suppression and Cushing's syndrome related to long-term corticosteroid exposure. Rare cardiovascular risks include specific cardiac arrhythmias.

Regulatory Safety Considerations

The safety profile includes specific notes concerning patient groups and duration of exposure. Effects associated with the beta2-agonist, such as tremor, are often temporary and may be more noticeable at the start of treatment. Conversely, systemic corticosteroid risks like decreased bone mineral density or cataracts are associated with high-dose, long-term exposure. Official prescribing information also notes the potential for a reduction in growth velocity in the pediatric population and advises caution in patients with pre-existing conditions such as severe cardiovascular disorders or diabetes mellitus.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Neumoterol is associated with using the medicine more frequently or at higher doses than prescribed. It is crucial to strictly follow your doctor’s instructions to avoid this risk. Overdosing on the active component of this inhaler has resulted in serious cardiovascular effects and, in rare instances, led to death.

Symptoms of Overdose

The physiological effects of an overdose primarily affect the cardiovascular and nervous systems, as well as electrolyte balance. Documented signs and symptoms include:

  • Cardiovascular: Chest pain (angina), fast or irregular heartbeats (tachycardia, up to 200 beats/minute), and high blood pressure.
  • Neurological: Tremors, nervousness, headache, dizziness, and seizures.
  • Metabolic: Low potassium levels in the blood (hypokalemia).

Emergency Actions

Immediate medical attention is required if you suspect an overdose or if your short-acting rescue inhaler is not working as effectively as usual, requiring you to use it more often. If an overdose is confirmed, the general medical response involves supportive care, including measures to stabilize vital functions.

Do not use this product in combination with any other medications containing a long-acting beta2-agonist, as this increases the risk of an overdose.

Therapeutic Uses of Neumoterol

Neumoterol is generally used in situations that require short-term symptomatic assistance and is applied across therapeutic domains where additional symptomatic support is needed to manage discomfort and tension. Because managing both acute and episodic discomfort is important, this medication may be part of symptomatic management in conditions marked by increased physiological stress.


Treating Acute Symptomatic Discomfort

This medication may be applied in situations involving symptoms related to physical discomfort that appear suddenly or intensify over time. It assists with supportive relief during difficult episodes, contributing to easing the overall symptom load. It is relevant in contexts involving acute or disruptive episodes that cause increased distress or discomfort, such as those involving symptoms of increased neurological or muscular activity, symptoms that create noticeable physiological strain, and symptoms related to systemic imbalance.

“It helps address symptom clusters that interfere with daily comfort, contributing to improved day-to-day stability during periods where symptoms are more noticeable.”

This provides support that helps ease the overall symptom burden during difficult episodes.

Quick Fact: Relief for Episodic Discomfort

Neumoterol is considered relevant in conditions characterized by episodic or fluctuating symptom manifestations.

Regulatory References

  1. MedlinePlus overview of Pain

Eligibility and Restrictions for Use

Who Can and Cannot Use Neumoterol?

Official regulatory documents define strict population eligibility for Neumoterol (Budesonide/Formoterol), classifying groups for whom use is approved, restricted, or prohibited.


Contraindicated Populations

Use of Neumoterol is contraindicated (explicitly prohibited) in the following groups:

  • Patients with documented hypersensitivity or allergy to budesonide, formoterol, or any product excipients.
  • It is not indicated for the primary treatment of status asthmaticus or acute episodes of bronchospasm.
  • The Formoterol component (LABA) must not be used as monotherapy (without the inhaled corticosteroid component) for asthma treatment.

Age-Related and Conditional Eligibility

Population Group Regulatory Eligibility Status
Approved Age Adults with COPD and patients 6 years of age and older for asthma maintenance
Pediatric Restriction Safety and efficacy have not been established in children younger than 6 years of age.
Hepatic Impairment Use with caution in severe liver disease, as increased drug exposure is expected.
Renal Impairment No data are available for use in patients with renal impairment.
Pregnancy/Lactation Conditional use only when the potential benefit to the mother outweighs possible risks to the child or fetus.

Eligibility-related warnings also advise caution for patients with certain cardiovascular disorders, uncontrolled diabetes mellitus, and untreated systemic infections.

What should I know about interactions with other medicines?

Neumoterol's interaction profile is derived from its two active ingredients and strictly defines conditions and restrictions for co-administration detailed in official government regulatory documents. The profile is structured around prohibiting certain combinations and identifying agents that alter drug exposure or produce additive physiological effects.

Interaction Category Regulatory Restriction Official Outcome
Other Long-Acting β₂-Agonists (LABAs) Contraindicated Risk of cumulative effects and overdose.
Monoamine Oxidase Inhibitors (MAOIs) Use with extreme caution May potentiate Formoterol's cardiovascular effects.
Tricyclic Antidepressants (TCAs) Use with extreme caution May potentiate Formoterol's cardiovascular effects.
β-Blockers Use with caution May block Formoterol’s effect, risking severe bronchospasm.
Diuretics, Xanthines, Other Steroids Use with caution May potentiate hypokalemia and/or ECG changes.
Exposure/Metabolic Interaction Official Regulatory Statement
Strong CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole) Increase systemic exposure to the Budesonide component by impeding metabolic clearance.
Grapefruit / Grapefruit Juice Documented potential to increase systemic exposure to Budesonide via CYP3A4 inhibition.
Severe Hepatic Impairment Noted to increase systemic exposure of both components due to reduced hepatic clearance.

The official interaction structure defines pharmacodynamic constraints by prohibiting co-administration with other LABAs and requiring restricted use with MAOIs and TCAs, including use limitations within two weeks of discontinuing those agents. The pharmacokinetic information highlights that agents reducing CYP3A4 activity can increase the body's systemic exposure to Budesonide.

Mechanism of Action

How Neumoterol Works

Neumoterol exerts its action through two distinct yet synergistic pharmacological mechanisms, governing bronchial smooth muscle tone and inflammatory responses.

Dual Modulation of Airway Muscle Tone and Gene Expression

The medicine functions across two fundamental biological domains: Autonomic Smooth Muscle Modulation and Intracellular Gene Transcription Control. Formoterol is a highly selective agonist of the beta2-Adrenoceptors (beta2-AR), which rapidly initiates the cAMP signaling cascade, leading to the sustained relaxation of bronchial smooth muscle. Simultaneously, Budesonide binds to the Glucocorticoid Receptor (GR) in cell cytoplasm, modulating gene expression (transcription) to actively suppress the production of pro-inflammatory mediators like cytokines and chemokines.

Mechanistic Synergy and Pathway Regulation

The two ingredients engage in an active synergy. Budesonide enhances the function of the beta2-AR by increasing its expression and sensitivity, modulating the pathway's response to chronic agonism. This integrated action maintains the beta2-AR expression and function, ensuring the continued efficacy of the bronchodilatory mechanism and regulating cellular responsiveness.

Dosage and Administration Information

Neumoterol (a combination of an inhaled corticosteroid and a long-acting beta2-agonist) is a maintenance treatment administered by oral inhalation only. It is not indicated for the immediate relief of acute bronchospasm; a separate short-acting rescue inhaler must be used for acute symptoms.

Official Administration and Dosing

Patient Group Recommended Dosage (Twice Daily) Administration Time
Adults and Adolescents (ge 12 years) for Asthma/COPD Two inhalations of the prescribed strength. Morning and Evening (approx. 12 hours apart)
Pediatric Patients (6 to <12 years) for Asthma Two inhalations of the lower strength (e.g., 80/4.5 mcg). Morning and Evening

Procedural Steps

  1. Priming: Before initial use, the inhaler must be shaken well and a specified number of test sprays (e.g., two or four) must be released into the air. This step must be repeated if the inhaler has not been used for more than the period specified in the official documentation (e.g., 5-7 days).
  2. Inhalation: Shake the inhaler well before each inhalation. After exhaling fully, close lips around the mouthpiece and press down firmly while inhaling deeply through the mouth.
  3. Post-Dose Rinse: After each two-inhalation dose, gargle and rinse the mouth with water and spit out the contents without swallowing. This is a mandatory step to help reduce the risk of localized infection in the mouth and throat.

Missed Dose

If a dose is missed, patients should skip the missed dose and take the next dose at the regularly scheduled time. Do not take extra inhalations to compensate for a missed dose. The maximum recommended daily dose is four inhalations total (two in the morning and two in the evening) and must not be exceeded.

Recent Clinical Evidence

Research evidence / Overview of studies for Neumoterol

Evidence for Use in Asthma Management

Randomized Controlled Trials (RCTs) were used in research exploring the use of this medicine as a controller therapy for persistent asthma in adults and adolescents. These studies were structured to monitor objective changes in lung function, such as the Forced Expiratory Volume in 1 second (FEV1), and tracked the frequency of severe asthma exacerbations (flares). Research highlights changes measured during the study period related to lung function and documented measurements recorded when compared to monotherapy or a placebo. Studies also reported on patterns observed in the measurement of the rate of exacerbations.


Evidence for Use in COPD Maintenance

Long-term Randomized Controlled Trials, often lasting six months to one year, were used to evaluate research into the use of this medicine for Chronic Obstructive Pulmonary Disease (COPD) maintenance. Key outcomes monitored were changes in lung function (FEV1) and the rate of COPD exacerbations. The regulatory evidence record notes that an increased occurrence of lower respiratory tract infections was observed in some COPD studies, which is a finding that defines the evidence landscape.


What Is Still Uncertain About Neumoterol Research

While research contributes to the broader evidence landscape, data for long-term outcomes are not fully established beyond the one-year mark in the core trials for either asthma or COPD. Furthermore, comparative evidence is lacking, meaning there is a limited number of studies designed to determine if this specific combination performs differently than all other comparable fixed-dose inhalers. Data for certain groups remain insufficient, especially for very young children under 6 years of age with asthma. These research limitations highlight what is known and what is still uncertain about the research record.

Frequently Asked Questions (FAQ)

Common questions about Neumoterol (FAQ)


Q: What does the patient leaflet mean by 'contraindications'?

A: According to the official product information, a contraindication is a condition or circumstance that makes the use of the medicine potentially harmful. It means that the drug is typically not administered in that specific situation. These are listed in the patient leaflet to help clarify the restrictions on the medicine’s use.


Q: Is it normal to feel extra tired when first taking Neumoterol?

A: Regulatory documents state that tiredness or fatigue has been documented as an uncommon side effect associated with the drug’s components. While not listed as a common effect, if this effect occurs and is a concern, it is advisable to consult a healthcare professional.


Q: Does Neumoterol affect your mood or cause anxiety?

A: Official information indicates that anxiety and depression are documented psychiatric side effects. These effects are typically categorized as uncommon or very rare adverse reactions associated with the components of the medicine.


Q: Are there any specific foods or drinks that should be avoided with Neumoterol?

A: Regulatory documents explicitly warn against consuming Grapefruit or Grapefruit Juice while taking this medicine. Grapefruit may increase the amount of the budesonide component that enters the bloodstream. No other common foods or drinks are explicitly listed as requiring avoidance in the regulatory documents.


Q: What are the long-term effects of taking Neumoterol for many years?

A: Official product information cautions that high-dose, long-term exposure to the corticosteroid component may lead to systemic effects. These effects can potentially include decreased bone mineral density or the formation of cataracts. The decision regarding long-term use is typically informed by the ongoing assessment of clinical risks and benefits.


Q: Can people with a known history of heart issues take Neumoterol?

A: Official guidance notes that caution is advised for patients with pre-existing severe cardiovascular disorders. This warning is due to the potential for the beta-agonist component to affect the cardiovascular system.


Q: Do I need a special type of prescription for Neumoterol?

A: According to official regulatory records, Neumoterol is categorized as a Human Prescription Drug. This classification means the product is dispensed through a prescription from an authorized healthcare professional and is not available over-the-counter.


Q: Does Neumoterol interact with common over-the-counter pain medicines?

A: Official drug interaction tables do not specifically list common over-the-counter pain medicines. However, the regulatory label warns that the combination may have additive effects with other medicines (like certain diuretics or other steroids) that could affect potassium levels.


Q: Is it okay to drink alcohol while taking Neumoterol?

A: While official interaction data may not list a direct chemical interaction, official guidance suggests that alcohol consumption may increase the severity of certain common side effects, such as headaches or nausea.


Q: How long does it take before Neumoterol starts to have an effect?

A: Studies indicate that the bronchodilator component (Formoterol) has a rapid onset of action. Some improvement in airway function may begin as early as 15 minutes following inhalation. However, since this is a maintenance treatment, the full therapeutic benefit may take several weeks of consistent use.


Q: How long does the medicine stay in my system after taking a dose?

A: Based on pharmacokinetic studies, the bronchodilator component (Formoterol) has an average terminal elimination half-life of approximately 7 to 10 hours after it is inhaled. This half-life reflects the duration of the drug’s elimination from the body following inhalation.


Q: Will I need to take Neumoterol for a long time or is it short-term use?

A: Neumoterol is officially indicated for long-term maintenance treatment of chronic respiratory conditions. It is designed to be a foundational medicine for sustained control, not a short-term solution for immediate symptoms.


Q: Can pregnant or breastfeeding people use Neumoterol?

A: The drug is generally recommended during pregnancy only if the potential benefits are judged to outweigh the possible risks to the child or fetus. Official information confirms that components of the medicine are excreted into human milk during lactation.


Q: Is Neumoterol suitable for older adults?

A: Official information suggests that the product can be used by older adults (ge65 years of age). Official prescribing information states that no special dosing requirements or adjustments are necessary for this age group.


Q: Can people with pre-existing kidney problems use Neumoterol?

A: According to official regulatory labels, no data are currently available regarding the safety or efficacy of the product in patients with renal impairment (kidney problems). The status requires careful consideration and monitoring by a healthcare professional.


Q: Is Neumoterol considered a new medication?

A: The active ingredient combination used in this medicine was first approved by the FDA in the US in 2006. This regulatory approval date helps establish its history within the medical community.


Q: Why are there different strengths of Neumoterol tablets available?

A: Different strengths are made available to allow for titration (adjusting the dose) based on the severity of the condition being treated. This ensures that a patient can be maintained on the lowest effective dose, as recommended by regulatory guidance.


Q: Does Neumoterol cause weight gain?

A: Weight gain is not listed as a commonly occurring side effect of the medicine. However, it is noted as a potential sign of Cushing's syndrome, which is a rare, severe systemic side effect associated with long-term use of high-dose corticosteroids.


Q: Is there a generic version of Neumoterol available?

A: The FDA has approved generic versions of the combination drug containing the active ingredients budesonide and formoterol. Generic versions contain the same active ingredients and are held to the same high standards of quality and performance as the brand-name product.


Q: What is the difference between Neumoterol and its generic name?

A: Neumoterol is the brand name used to market this medicine. The official generic name refers to the two active ingredients it contains: budesonide and formoterol fumarate dihydrate.


Q: Is Neumoterol known to be habit-forming?

A: Official regulatory sources, such as the DEA Schedule in the US, classify this product as Not a Controlled Drug. Therefore, it is not listed as being habit-forming or having a high potential for abuse.


Q: What should I do if I think I've taken too much Neumoterol?

A: Regulatory information describes the possible symptoms of overdose, which primarily relate to the beta-agonist component and can include rapid heart rate, headache, and tremor. It is important that any use exceeding the prescribed amount is promptly brought to the attention of a healthcare provider.


Q: Does Neumoterol interact with birth control medication?

A: Official drug interaction information notes that estrogens, often found in oral birth control medications, may increase the blood levels of the budesonide component. This potential change in exposure could increase the risk of systemic corticosteroid side effects.


Q: Does Neumoterol affect the results of certain medical tests?

A: Official regulatory sources note that the medicine may cause changes in the results of certain blood tests. Specifically, it can affect levels of blood sugar (hyperglycemia) and potassium (hypokalemia) levels.


Q: What are the signs that Neumoterol might not be working for someone?

A: The regulatory label notes that a key sign of a deteriorating condition is an increasing need to use a short-acting rescue inhaler. If this occurs, regulatory guidance indicates that a prompt medical re-evaluation is warranted.


Q: Do the side effects of Neumoterol go away over time?

A: Regulatory notes state that some effects, particularly those related to the beta-agonist component like tremor, are often temporary and may be most noticeable when the treatment is first started. Other side effects should be monitored and discussed with a healthcare provider if they persist.


Q: Does Neumoterol come in forms other than tablets, like a liquid or injection?

A: Official documentation states that the product is supplied only for oral inhalation. The available forms are typically an inhalation powder or an inhalation aerosol metered-dose device.


Q: Is Neumoterol prescribed to people with autoimmune conditions?

A: Official regulatory warnings advise caution for patients with various pre-existing conditions, including those with untreated systemic infections. There is no direct contraindication against use in patients with autoimmune conditions, provided all infections are appropriately treated.


Q: What does the information say about stopping Neumoterol suddenly?

A: Regulatory information notes that patients are advised to avoid sudden discontinuation of this drug on their own. Discontinuing the medicine, particularly the corticosteroid component, must be managed and supervised by a healthcare provider.


Q: Is there a maximum length of time Neumoterol can be used for?

A: Since the drug is indicated for long-term maintenance of chronic conditions, there is no specific maximum duration of use defined in the regulatory documents. Treatment duration is determined by the ongoing medical assessment of the patient's condition.


Q: Why do official sources list so many possible interactions for Neumoterol?

A: The official documentation for this medicine lists an extensive number of possible interactions because it is a dual-component drug. Both the inhaled corticosteroid and the long-acting beta-agonist have separate regulatory interaction profiles that must be combined and documented.


Q: Why is Neumoterol sometimes given with other medications?

A: This maintenance medicine is often prescribed alongside a separate short-acting beta2-agonist (SABA) rescue inhaler. This is because Neumoterol is not designed or indicated to provide immediate relief for acute or sudden symptoms.


Q: Can I take Neumoterol if I'm taking blood thinners?

A: Official regulatory data notes that the budesonide component may alter the effects of warfarin, which is a common blood thinner. If used concurrently, official guidance suggests careful monitoring by a healthcare provider for potential changes in bleeding risk.

How should Neumoterol be stored and disposed of?

Storage Conditions

Official regulatory documents require that the product be stored not above 30 C (86 F) and must not be frozen. The medicine should be kept in its original container and protected from light and moisture. After removing the dry powder inhaler from its sealed foil pouch, it must be used within 3 months. The product must also be kept out of the sight and reach of children.

Disposal Instructions

Any unused medicine or waste material must be disposed of in accordance with local requirements. The pressurized container, such as the inhalation aerosol, has special handling requirements and must not be broken, punctured, or burnt, even when it is empty.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neumoterol found in:

A-Z Index: